 Home > Medical News > Latest Medical News > Nuocheng Jianhua's new drug ICP-723 is selected as one of the 100 new technologies and new products of the Zhongguancun Forum in 2021

Nuocheng Jianhua's new drug ICP-723 is selected as one of the 100 new technologies and new products of the Zhongguancun Forum in 2021

 Last Update: 2021-10-10
 Source: Internet
 Author: User

Tags

applied flow technology

class fly ash

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Beijing, September 29, 2021/PRNewswire/ - Biomedical high-tech company Nuocheng Jianhua (Hong Kong Stock Exchange code: 09969) today announced that the company's self-developed second-generation pan-TRK inhibitor ICP-723 has been selected 2021 Zhongguancun International Technology Trade Conference 100 new technologies and new products list
.

On September 27-28, as one of the six major sections of the 2021 Zhongguancun Forum, the Zhongguancun International Technology Exchange Conference released a list of 100 new technologies and new products, and a total of 10 new technologies and new products in the biomedical field were selected
.

ICP-723 is a Class 1 innovative drug with independent intellectual property rights owned by Nuocheng Jianhua worldwide.
It is used to treat advanced or metastatic solid tumors carrying NTRK fusion genes, including lung cancer, breast cancer, colorectal cancer, thyroid cancer, etc.
, and Patients who are resistant to the first generation of TRK inhibitors
.

Currently, ICP-723 is conducting clinical trials in China and the United States

Dr.
Cui Jisong, co-founder, chairman and CEO of Nuocheng Jianhua, said: "Zhongguancun International Technology Trade Conference focuses on high-quality scientific and technological achievements, projects, new technologies, new products and application technology needs
.

I am very pleased that our ICP-723 can Stand out from many projects and become a new technology that represents the field of biomedicine

In 2021, led by the Zhongguancun Broadband Wireless Private Network Industry Alliance, relying on the Science Development Bureau of the Chinese Academy of Sciences, the Beijing Association for Science and Technology, and the Association of Foreign Investment Eight major fields, including equipment, new energy and new materials, energy conservation and environmental protection, and intelligent manufacturing, solicit new technology and new product projects from the society
.

Through the three methods of targeted invitation, unit recommendation and public solicitation, the Zhongguancun International Technology Exchange Conference finally collected more than 700 new technologies and new products from nearly 600 institutions in 12 countries and regions

About Nuocheng Jianhua

Nuocheng Jianhua (Hong Kong Stock Exchange code: 09969) is a commercialized biomedical high-tech company, focusing on the development of a class of new drugs in the treatment of malignant tumors and autoimmune diseases, suitable for the treatment of lymphoma and solid tumors And autoimmune diseases
.

Several new drug products are currently in commercialization, clinical and pre-clinical research and development stages

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.